OBJECTIVES: To evaluate the efficacy and treatment-related @entity137 of accelerated hyperfractionation field-involved re-irradiation combined with concurrent @entity416 chemotherapy for locally recurrent and irresectable @entity5 (LRIRC). METHODS: 72 @entity1 with LRIRC who underwent the treatment were studied. Three-dimensional conformal accelerated hyperfractionation radiotherapy (3D-CAHRT) was performed and the dose was delivered with a schedule of 1.2 Gy twice daily, with an interval of at least 6 h between fractions, 5 days a week. Concurrent @entity416 chemotherapy was administered twice daily. After 36 Gy in 30 fractions over 3 weeks, @entity1 were evaluated to define the resectability of the disease. If resection was not feasible irradiation was resumed until the total dose administered to the @entity5 reached 51.6-56.4 Gy. RESULTS: Two @entity1 temporarily interrupted concurrent chemoradiation because of Grade IV @entity294 . The remaining 70 @entity1 completed the planned concurrent chemoradiation. In all @entity1 , the complete response rate was 8.3% and the partial response rate was 51.4%. The overall response rate was 59.7% and clinical benefit rate was 93.1%. Symptomatic responses proved to be obvious and @entity5 resection was performed in 18 @entity1 . The overall median survival time and median progression-free survival time were 32 and 17 months, respectively. 3 year overall survival and progression-free survival were 45.12% and 31.19%, respectively. Severely acute @entity137 included Grade III-IV @entity294 and @entity3028 with 9.7% and 8.3% incidence respectively. @entity1744 was severely late @entity137 , and the incidence was 1.4%. CONCLUSION: Three-dimensional conformal accelerated hyperfractionation field-involved re-irradiation combined with concurrent @entity416 chemotherapy might be an effective and well-tolerated regimen for @entity1 with LRIRC.

Accelerated hyperfractionation field-involved re-irradiation combined with concurrent @entity416 chemotherapy for locally recurrent and irresectable XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['rectal cancer', 'tumour'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea'] @entity3028 :: ('MESH:D000380', 'Disease') :: ['granulocytopenia'] @entity1744 :: ('MESH:D043183', 'Disease') :: ['Small bowel obstruction']
@entity5 :: (MESH:D009369,Disease) :: ['rectal cancer']
